<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841137</url>
  </required_header>
  <id_info>
    <org_study_id>16CDN-Prg02</org_study_id>
    <nct_id>NCT02841137</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Progesterone Tablet in Post-menopausal Women</brief_title>
  <official_title>Effect of Progesterone 5, 10, and 20 mg Tablets Compared To Progesterone 100 mg Capsules on the Endometrial Thickness of Post-Menopausal Women Under Hormone Therapy - A Prospective, Open-Label, Randomized, Four-Arm, Parallel-Group, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study intended to determine the effect of progesterone 5, 10 and 20 mg
      tablets compared to progesterone 100 mg capsules on the endometrial thickness of
      post-menopausal women under hormone therapy with estradiol.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometrial thickness change towards baseline (mm)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>histological assessment of the endometrium (presence of hyperplasia or proliferation)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding (presence or absence)</measure>
    <time_frame>everyday over 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (MENQOL Questionnaire)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep scale from the Medical Outcomes Study (MOS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>progesterone 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 10 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progesterone 20 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>progesterone 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>progesterone 100 mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>comparison of different dosages of drug towards the active comparator</description>
    <arm_group_label>progesterone 5 mg</arm_group_label>
    <arm_group_label>progesterone 10 mg</arm_group_label>
    <arm_group_label>progesterone 20 mg</arm_group_label>
    <arm_group_label>progesterone 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Availability for the entire study period

          2. Post-menopausal female defined as:

               -  at least 12 consecutive months of spontaneous amenorrhea and

               -  less than 10 years of spontaneous amenorrhea, and

               -  Follicle-stimulating hormone (FSH) levels &gt; 40 milli International Units/ml

          3. Females with an intact uterus

          4. Moderate to severe climacteric vasomotor symptoms

          5. Aged of at least 40 years but not older than 65 years

          6. Body mass index (BMI) greater than or equal to 18.00 kg/m2 and below 30.00 kg/m2

          7. Non- or ex-smoker;

          8. Endometrium thickness â‰¤4 mm on ultrasonography at screening

          9. Negative mammogram (dated &lt; 2 years)

         10. Negative Pap smear test (dated &lt; 1 year)

         11. Normal clinical breast examination

         12. Normal pelvic examination

         13. Have no clinically significant diseases captured in the medical history or evidence of
             clinically significant findings on physical examination, as determined by the medical
             investigator

         14. Willingness to adhere to the protocol requirements as evidenced by the informed
             consent form (ICF) duly read, signed and dated by the subject

        Exclusion Criteria:

          1. Use of any estrogen, progestin, or estrogen/progestin drug products, androgens,
             selective estrogen receptor modulators (SERMs), phytoestrogen supplements or natural
             products (soy, black cohosh, dong quai) during the past 3 months before the screening
             visit

          2. Use of any estrogen, progestin or androgen pellet or injectable therapy during the
             past 6 months before the screening visit

          3. Contraindications to hormone therapy:

               -  Active liver dysfunction or disease or history of severe liver disease

               -  Known, suspected or past history of hepatic tumors (benign or malign)

               -  Active or past history of arterial thromboembolic disease (e.g. angina,
                  myocardial infarction, stroke, coronary heart disease, transient ischemic attack)

               -  Active or past history of venous thromboembolism (e.g. deep venous thrombosis,
                  pulmonary embolism) or active thrombophlebitis

               -  Known, suspected or past history of breast cancer

               -  Known, suspected or past history of estrogen-dependent or progestin-dependent
                  malignant neoplasia (e.g. endometrial cancer)

               -  Endometrial hyperplasia

               -  Porphyria cutanea tarda

               -  Genital bleeding

               -  Untreated hypertension

               -  Classical migraine

               -  Partial or complete loss of vision or diplopia due to ophthalmic vascular disease

          4. Presence of clinically significant screening ECG abnormalities as defined by medical
             judgment

          5. Presence of polyps

          6. Presence of uterine fibroids or other abnormalities affecting endometrial thickness
             measurement or precluding estrogen therapy

          7. Known hypersensitivity to the active substances or to any of the excipients contained
             in the drug products in particular to soya or peanut, as well as hereditary problems
             of fructose intolerance or phenylketonuria

          8. Participation in a concurrent clinical trial or another trial within the past 2 months

          9. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and
             St John's Wort), in the previous 28 days before day 1 of this study

         10. Maintenance therapy with any drug or significant history of drug dependency, drug
             abuse or alcohol abuse within the last 2 years

         11. Presence of any medical condition or other circumstances which would significantly
             decrease the chance of obtaining reliable data, achieving study objectives or
             completing the study

         12. Serious psychiatric problems (whether or not receiving treatment) or in any case such
             as to compromise the patient's reliability

         13. Any clinically significant illness in the previous 28 days before day 1 of this study

         14. Any history of tuberculosis and/or prophylaxis for tuberculosis

         15. Positive screening of alcohol and/or drugs of abuse

         16. Positive results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus
             tests

         17. Females who are pregnant according to a positive serum pregnancy test

         18. Presumption of subject's poor reliability/cooperation

         19. Any reason which, in the opinion of the Investigator, would prevent the subject from
             participating in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deschamps</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algorithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Mont-Royal</city>
        <state>Quebec</state>
        <zip>H3P3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

